Brief: Merck Enters Five-Year Agreement To Provide End-To-End Testing Services For Genetix Biotherapeutics' Commercial Therapies
07/05/2026 13:14
May 7 (Reuters) - Merck KGaA MRCG.DE: ENTERS FIVE-YEAR AGREEMENT TO PROVIDE END-TO-END TESTING SERVICES FOR GENETIX BIOTHERAPEUTICS' COMMERCIAL THERAPIES Source text: [ID:] Further company coverage: MRCG.DE (Gdansk Newsroom) ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Merck KGaA
See all newsEurope Research Roundup: ASML Holding, Douglas, Richemont
European shares lifted by miners and tech; Mideast in focus (updated)
Merck jumps as lab demand lifts 2026 outlook
Brief: Merck Enters Five-Year Agreement To Provide End-To-End Testing Services For Genetix Biotherapeutics' Commercial Therapies
Factbox: Global pharma companies that have publicly announced Trump drug pricing agreements